Literature DB >> 24025802

Network-based approaches in drug discovery and early development.

J M Harrold1, M Ramanathan, D E Mager.   

Abstract

Identification of novel targets is a critical first step in the drug discovery and development process. Most diseases such as cancer, metabolic disorders, and neurological disorders are complex, and their pathogenesis involves multiple genetic and environmental factors. Finding a viable drug target-drug combination with high potential for yielding clinical success within the efficacy-toxicity spectrum is extremely challenging. Many examples are now available in which network-based approaches show potential for the identification of novel targets and for the repositioning of established targets. The objective of this article is to highlight network approaches for identifying novel targets with greater chances of gaining approved drugs with maximal efficacy and minimal side effects. Further enhancement of these approaches may emerge from effectively integrating computational systems biology with pharmacodynamic systems analysis. Coupling genomics, proteomics, and metabolomics databases with systems pharmacology modeling may aid in the development of disease-specific networks that can be further used to build confidence in target identification.

Entities:  

Mesh:

Year:  2013        PMID: 24025802      PMCID: PMC4701200          DOI: 10.1038/clpt.2013.176

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  66 in total

1.  Range-based attack on links in scale-free networks: are long-range links responsible for the small-world phenomenon?

Authors:  Adilson E Motter; Takashi Nishikawa; Ying-Cheng Lai
Journal:  Phys Rev E Stat Nonlin Soft Matter Phys       Date:  2002-12-30

2.  The human disease network.

Authors:  Kwang-Il Goh; Michael E Cusick; David Valle; Barton Childs; Marc Vidal; Albert-László Barabási
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-14       Impact factor: 11.205

3.  Pathway Tools version 13.0: integrated software for pathway/genome informatics and systems biology.

Authors:  Peter D Karp; Suzanne M Paley; Markus Krummenacker; Mario Latendresse; Joseph M Dale; Thomas J Lee; Pallavi Kaipa; Fred Gilham; Aaron Spaulding; Liviu Popescu; Tomer Altman; Ian Paulsen; Ingrid M Keseler; Ron Caspi
Journal:  Brief Bioinform       Date:  2009-12-02       Impact factor: 11.622

4.  Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes?

Authors:  S M Haffner; M P Stern; H P Hazuda; B D Mitchell; J K Patterson
Journal:  JAMA       Date:  1990-06-06       Impact factor: 56.272

5.  Systems pharmacology for drug discovery and development: paradigm shift or flash in the pan?

Authors:  P Vicini; P H van der Graaf
Journal:  Clin Pharmacol Ther       Date:  2013-05       Impact factor: 6.875

Review 6.  Systems pharmacology: network analysis to identify multiscale mechanisms of drug action.

Authors:  Shan Zhao; Ravi Iyengar
Journal:  Annu Rev Pharmacol Toxicol       Date:  2012       Impact factor: 13.820

7.  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.

Authors:  Philip D Home; Stuart J Pocock; Henning Beck-Nielsen; Paula S Curtis; Ramon Gomis; Markolf Hanefeld; Nigel P Jones; Michel Komajda; John J V McMurray
Journal:  Lancet       Date:  2009-06-06       Impact factor: 79.321

8.  Computational modeling of ERBB2-amplified breast cancer identifies combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitors.

Authors:  Daniel C Kirouac; Jin Y Du; Johanna Lahdenranta; Ryan Overland; Defne Yarar; Violette Paragas; Emily Pace; Charlotte F McDonagh; Ulrik B Nielsen; Matthew D Onsum
Journal:  Sci Signal       Date:  2013-08-13       Impact factor: 8.192

9.  Boolean network simulations for life scientists.

Authors:  István Albert; Juilee Thakar; Song Li; Ranran Zhang; Réka Albert
Journal:  Source Code Biol Med       Date:  2008-11-14

10.  A side effect resource to capture phenotypic effects of drugs.

Authors:  Michael Kuhn; Monica Campillos; Ivica Letunic; Lars Juhl Jensen; Peer Bork
Journal:  Mol Syst Biol       Date:  2010-01-19       Impact factor: 11.429

View more
  39 in total

1.  Translational intracerebral hemorrhage: a need for transparent descriptions of fresh tissue sampling and preclinical model quality.

Authors:  Che-Feng Chang; Li Cai; Jian Wang
Journal:  Transl Stroke Res       Date:  2015-04-25       Impact factor: 6.829

Review 2.  Boolean network modeling in systems pharmacology.

Authors:  Peter Bloomingdale; Van Anh Nguyen; Jin Niu; Donald E Mager
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-01-06       Impact factor: 2.745

3.  Cooperative Targets of Combined mTOR/HDAC Inhibition Promote MYC Degradation.

Authors:  John K Simmons; Aleksandra M Michalowski; Benjamin J Gamache; Wendy DuBois; Jyoti Patel; Ke Zhang; Joy Gary; Shuling Zhang; Snehal Gaikwad; Daniel Connors; Nicholas Watson; Elena Leon; Jin-Qiu Chen; W Michael Kuehl; Maxwell P Lee; Adriana Zingone; Ola Landgren; Peter Ordentlich; Jing Huang; Beverly A Mock
Journal:  Mol Cancer Ther       Date:  2017-05-18       Impact factor: 6.261

Review 4.  Constellation pharmacology: a new paradigm for drug discovery.

Authors:  Russell W Teichert; Eric W Schmidt; Baldomero M Olivera
Journal:  Annu Rev Pharmacol Toxicol       Date:  2015       Impact factor: 13.820

5.  Design of Gallinamide A Analogs as Potent Inhibitors of the Cysteine Proteases Human Cathepsin L and Trypanosoma cruzi Cruzain.

Authors:  Paul D Boudreau; Bailey W Miller; Laura-Isobel McCall; Jehad Almaliti; Raphael Reher; Ken Hirata; Thu Le; Jair L Siqueira-Neto; Vivian Hook; William H Gerwick
Journal:  J Med Chem       Date:  2019-10-04       Impact factor: 7.446

6.  A Perspective on Implementing a Quantitative Systems Pharmacology Platform for Drug Discovery and the Advancement of Personalized Medicine.

Authors:  Andrew M Stern; Mark E Schurdak; Ivet Bahar; Jeremy M Berg; D Lansing Taylor
Journal:  J Biomol Screen       Date:  2016-03-08

7.  Logic-Based and Cellular Pharmacodynamic Modeling of Bortezomib Responses in U266 Human Myeloma Cells.

Authors:  Vaishali L Chudasama; Meric A Ovacik; Darrell R Abernethy; Donald E Mager
Journal:  J Pharmacol Exp Ther       Date:  2015-07-10       Impact factor: 4.030

Review 8.  Drug repositioning approaches for the discovery of new therapeutics for Alzheimer's disease.

Authors:  Tae-Wan Kim
Journal:  Neurotherapeutics       Date:  2015-01       Impact factor: 7.620

9.  Network-Based Analysis of Bortezomib Pharmacodynamic Heterogeneity in Multiple Myeloma Cells.

Authors:  Vidya Ramakrishnan; Donald E Mager
Journal:  J Pharmacol Exp Ther       Date:  2018-04-09       Impact factor: 4.030

Review 10.  Machine and deep learning approaches for cancer drug repurposing.

Authors:  Naiem T Issa; Vasileios Stathias; Stephan Schürer; Sivanesan Dakshanamurthy
Journal:  Semin Cancer Biol       Date:  2020-01-03       Impact factor: 15.707

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.